PVR and neoplasm: In addition to membrane CD155, soluble isoforms can alter interactions between IC and its ligands, leading to resistance to immunotherapy; therefore, evaluating the production of different CD155 isoforms by tumor cells will be relevant for the success of immunotherapies.